Hepion Pharmaceuticals | 10-Q: FY2025 Q2 Revenue: USD 0

Revenue: As of FY2025 Q2, the actual value is USD 0.

EPS: As of FY2025 Q2, the actual value is USD -1.

EBIT: As of FY2025 Q2, the actual value is USD -3.026 M.

Financial Metrics

Operating Expenses

• Research and Development: $423,277 for the three months ended June 30, 2025, compared to $7,136,679 for the same period in 2024, representing a decrease of $6,713,402.
• General and Administrative: $919,488 for the three months ended June 30, 2025, compared to $1,367,169 for the same period in 2024, representing a decrease of $447,681.
• Asset Impairment Loss: $402,746 for the three months ended June 30, 2025, with no comparable expense in 2024.

Net Loss

• Net Loss: $1,042,572 for the three months ended June 30, 2025, compared to $3,925,212 for the same period in 2024, representing a decrease in net loss of $2,882,640.

Cash Flow

• Net Cash Used in Operating Activities: -$2,492,782 for the six months ended June 30, 2025, compared to -$14,545,497 for the same period in 2024.
• Net Cash Used in Investing Activities: -$132,117 for the six months ended June 30, 2025, with no comparable cash flow in 2024.
• Net Cash Provided by Financing Activities: $5,142,886 for the six months ended June 30, 2025, compared to $1,849,707 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company is focusing on the development and commercialization of diagnostic tests for celiac disease, respiratory multiplex, and H. pylori, which have CE marks and are eligible for sale in the EU and certain other markets, excluding the United States.
• Non-Core Business: The company has divested its Rencofilstat assets to Panetta Partners Limited, with contingent value rights for potential future payments based on regulatory and sales milestones.
• Priority: The company emphasizes the need for additional financing to continue operations and achieve profitability, with a focus on leveraging its licensed diagnostic assets.